Navigation Links
Anthera Pharmaceuticals Reports 2010 Third Quarter Financial Results and Operational Update

HAYWARD, Calif., Nov. 2, 2010 /PRNewswire-FirstCall/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), today announced financial results and business highlights for the third quarter ended September 30, 2010.

Financial Results

Total operating expenses for the third quarter ended September 30, 2010, were $8.4 million, as compared to $3.4 million for the same period in 2009. For the nine months ended September 30, 2010, total operating expenses were $22.8 million, as compared to $10.5 million for the same period in 2009. The increase in operating expenses during the quarter and year-to-date ended September 30, 2010 was primarily the result of increased site qualifications and clinical enrollment in the Company's Phase 3 clinical study VISTA-16 (Vascular Inflammation Suppression to Treat Acute Coronary Syndrome - 16 Weeks) and clinical enrollment and manufacturing development activities for Anthera's A-623 Phase 2b study, known as PEARL-SC (A Randomized, Double-Blind Phase 2b Study to Evaluate the Efficacy, Safety, and Tolerability of A623 AdministRation in Subjects with Systemic Lupus Erythematosus). The quarterly and year-to-date results also reflect the expected increase in professional services and other costs associated with operating as a public company.

Anthera ended the third quarter of 2010 with approximately $73.1 million in cash and cash equivalents and short-term investments. Included in this amount is approximately $29.1 million in net proceeds pursuant to a private placement offering which closed on September 24, 2010. On November 1, 2010 the Department of Treasury notified Anthera that approximately $1.0M in grants have been approved under section 48D of the Internal Revenue Service code.

Recent Business Highlights


  • During the third quarter, enrollment, site qualification and start-up activities continued for the PEARL-SC Phase 2b study, which is examining the therapeutic benefit of A-623 in patients with systemic lupus erythematosus (lupus).  Enrollment has begun in the United States and, subsequent to the third quarter, sites in Colombia and Mexico were initiated and are enrolling patients. The study remains on track for a biomarker analysis in the first half of 2011.  The primary endpoint of the PEARL-SC study will be an SLE responder index.  Details regarding the study can be found at
  • VISTA-16 site activations and patient enrollment are on schedule as of the end of the third quarter. Regulatory approvals and site initiations are ongoing in additional geographies. Stephen Nicholls, MD, John Kastelein, MD, and Greg Schwartz, MD, along with the Cleveland Clinic Coordinating Center for Clinical Research (C5), are providing executive oversight of the study.
  • Site monitoring and audits continue for the VISTA-16 study which is designed to reduce inflammation in high-risk patients following an ACS. Details regarding the study can be found at
  • The Journal of the American College of Cardiology (JACC) published an article in September 2010 based upon the FRANCIS study, which is investigating the effects of varespladib methyl on cardiovascular biomarkers in ACS patients.
  • IMPACTS Phase 2 final study report is expected before the end of the year. Options for the next stage of development are under review and protocol is currently being finalized.

  • Manufacturing

  • The second manufacturing campaign of A-623 clinical material was completed and passed all quality assurance specifications.
  • The Company continues to make progress with potential manufacturing partners for Phase 3.

  • In conjunction with the release of financial results for the third quarter ended September 30, 2010, Anthera will host a conference call at 5 pm Eastern Time, November 2, 2010. U.S. and Canadian participants may dial (877) 312-8807; international participants may dial (253) 237-1190. The conference ID is 19111226. To access the 24-hour audio replay, U.S. and Canadian participants may dial (800) 642-1687; international participants may dial (706) 645-9291. The conference ID for the replay is 19111226. The audio replay will be available until November 9, 2010. This conference call will be webcast live and archived on Anthera's website until November 2, 2011,

    About Anthera Pharmaceuticals

    Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. Anthera has one Phase 3 clinical program, varespladib, and two Phase 2 clinical programs, A-623 and A-001. Varespladib and A-001 inhibit a novel enzyme target known as sPLA2 . Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease (CAD). Anthera's Phase 2 product candidate, A-623, targets elevated levels of B-lymphocyte stimulator, or (BAFF), which has been associated with a variety of B-Cell mediated autoimmune diseases, including systemic lupus erythematosus (lupus). For more information, please visit

    Safe Harbor Statement

    Any statements contained in this press release that refer to future events or other non-historical matters are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These include, but are not limited to, statements relating to the anticipated initiation of Anthera's clinical studies, anticipated duration and expected results of these studies, and the progression of Anthera's products through future stages of clinical development. These forward-looking statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially as set forth in the Company's public filings with the Securities and Exchange Commission, including Anthera's Quarterly Report on Form 10-Q for the quarter ended June 30, 2010. Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.

    CONTACT: Bianca Nery of Anthera Pharmaceuticals, Inc., or 510-856-5586.ANTHERA PHARMACEUTICALS, INC.A Development Stage CompanySTATEMENT OF OPERATIONS(unaudited)Three Months Ended September 30,Nine Months Ended September 30,2010200920102009OPERATING EXPENSE:  Research and development

    7,727,129  General and administrative

    1,510,021884,9084,244,0002,730,482Total operating expense

    8,395,1463,410,85622,809,08810,457,611LOSS FROM OPERATIONS:

    (8,395,146)(3,410,856)(22,809,088)(10,457,611)OTHER INCOME (EXPENSE):Interest and other income

    61,606-76,56221,559Interest and other expense

    -(193,556)(4,641,169)(289,776)Total other income (expense)

    61,606(193,556)(4,564,607)(268,217)NET LOSS

    $  (8,333,540)$   (3,604,412)$  (27,373,695)$   (10,725,828)Net loss per share--basic and diluted

    (7.16) Weighted-average number of shares used in
    per share calculation-- basic and diluted

    22,964,2791,520,87519,567,0581,498,108ANTHERA PHARMACEUTICALS, INC.A Development Stage CompanyBALANCE SHEET DATA(unaudited)September 30,
    2010December 31,
    2009Cash and cash equivalents

    3,803,384Short term investments

    21,878,890Total assets

    5,888,789Total notes payable

    3,129,877Total warrant and derivative liabilities

    406,130Total current liabilities

    8,167,645Deficit accumulated during development stage

    $  (92,603,647)$  (65,229,952)Total shareholders' equity (deficit)

    70,085,498$  (12,278,856)Common shares outstanding

    32,796,6901,566,199Preferred shares outstanding


    SOURCE Anthera Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Anthera Announces Third Quarter 2010 Financial Report and Conference Call
    2. Anthera Pharmaceuticals Announces Pricing of $31.5 Million PIPE Financing
    3. Anthera Pharmaceuticals to Present at Deutsche Bank Securities 35th Annual Health Care Conference
    4. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
    5. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
    6. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
    7. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
    8. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
    9. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
    10. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
    11. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
    Post Your Comments:
    (Date:10/9/2015)... , Schweiz, October 9, 2015 Der ... an Dr.   Yutaka Kondo und Dr.   Junko ... Award   2015 " geht an Dr.   ... --> Der " JCA-Mauvernay Award   2015 ... und Dr.   Junko Takita    ™ , ...
    (Date:10/8/2015)... PITTSBURGH , Oct. 8, 2015  Mylan N.V. ... will host a conference call and webcast on Tuesday, ... review the value to be created for shareholders of ... Mylan,s offer to acquire the company. During the call, ... compelling proposition for Perrigo shareholders. Mylan,s offer represents a ...
    (Date:10/8/2015)... , Oct. 8, 2015  The National Heart, ... $40 million to the Broad Institute of MIT ... of 20,000 individuals, as well as data to ... profiling. Trans-Omics for Precision Medicine ... toward a larger initiative, which will use whole ...
    Breaking Medicine Technology:
    ... 20 Kinetic Systems, Inc., a leading global provider ... general industry clients, announced today the appointment of Peter ... well as to its Board of Directors. He will ... Mr. Maris has been with Kinetics for ...
    ... Sept. 20 Accuray Incorporated (Nasdaq: ARAY ), ... that its management is scheduled to present at the JMP ... 28, 2010 at 11:30 a.m. ET/8:30 a.m. PT. ... from the investor relations page of the Company,s Web site ...
    Cached Medicine Technology:
    (Date:10/10/2015)... ... October 10, 2015 , ... Isabel Healthcare will participate in the Cerner Health ... the release of the Institute of Medicine’s latest report “Improving Diagnosis in Healthcare”, Isabel ... that assist healthcare providers and consumers to potentially reduce the chance of error. The ...
    (Date:10/10/2015)... ... October 10, 2015 , ... In the inaugural people’s choice contest, entitled ... To Work in Jacksonville, amongst medium-sized companies with 25 – 99 employees. The announcement ... with a celebratory gala on October 1st. , Many of the features of ...
    (Date:10/9/2015)... California (PRWEB) , ... October 09, 2015 , ... ... Osteopathic Medicine of the Pacific Associate Dean for Graduate Medical Education J. Michael ... of the Year Award. Finley was selected for his impact on graduate medical ...
    (Date:10/9/2015)... Los Angeles, CA (PRWEB) , ... October 09, 2015 , ... ... awareness for breast cancer victims, survivors, and the ongoing effort to find a cure. ... patients another outlet for helping women in need. With their Bra Collection Campaign, Beverly ...
    (Date:10/9/2015)... ... October 09, 2015 , ... A new health tool that helps identify if ... online ( ) – just in time for the cold and flu season, ... However, for many in the U.S., the real start of cold/flu season is the ...
    Breaking Medicine News(10 mins):
    ... ... medical journal Osteoporosis International found that women taking AdvaCAL® calcium had the highest bone ... 32 studies involved 3,169 postmenopausal women, 79 skeletal measures and 7 different types of ... ...
    ... ... Dermatologist settled in Dubai, received the very prestigious ,HIND RATTAN AWARD, this ... Rattan was presented at a ceremony in connection with the yearly International ... Heavy Industries and Public Enterprises, Government of India. Dr. Mehta was awarded ...
    ... ... IL based management consulting and technology firm, today announced it will merge ... Gold Certified Partner, effective January 1, 2010. Logan Consulting is ... America, Europe and Asia since 1992. Under the new structure, ...
    ... , ... Omnetics Connector Corporation, the leading manufacturer of miniature high-rel connectors, is utilizing their ... , ... MN (Vocus) January 29, 2010 -- Omnetics Connector Corporation, the leading manufacturer of ...
    ... ... Vemma Nutrition Company launches Vemma ... or other sports drinks, Vemma THIRST goes beyond hydration by ... minerals, while replenishing the body with necessary electrolytes, specialized carbohydrates ...
    ... , , Majority of Mississippi ... Jan. 28 The following is a statement by ... Consumer Healthcare Products Association (CHPA): , "Today, the Mississippi ... that, if it becomes law, will greatly limit how cold and ...
    Cached Medicine News:
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    Medicine Products: